Reviews & Comments
ABSA Comments on the Federal Register Docket CDC-2012-0010: Influenza Viruses Containing the Hemagglutinin from the Goose/Guangdong/1/96 Lineage (PDF 236KB)
a letter written by Barbara Fox Nellis, RBP, CBSP, President, ABSA, 14 December, 2012
ABSA Comments on the draft National Action Plan
to Prevent Health-care Infections announced in the April 25th, 2012 Federal Register. (PDF 264KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA,
7 June, 2012
ABSA Comments on the October 3, 2011
Federal Register announcement regarding the
proposed revisions to the Foreign Quarantine; Etiological Agents, Hosts, and Vectors
standard announced in the Federal Register on October 14, 2011. (PDF 560KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA,
12 December, 2011
ABSA Comments on the October 3, 2011
Federal Register announcement regarding the
proposed revisions to the Possession, Use, and Transfer, of Select Agents
and Toxins standard. (PDF 176KB)
a letter written by LouAnn Crawford Burnett, MS, CBSP, President, ABSA,
30 November, 2011
Federal Experts Security Advisory Panel Meeting(PDF 307KB) a presentation by Michelle McKinney, MS, CBSP ABSA Councilor, July 21, 2011
ABSA Comments on the proposed
revisions to the "NIH Guidelines for Research with Recombinant DNA (NIH
Guidelines)" which were announced in the Federal Register on July 25, 2011. (PDF 140KB)
a letter written by Karen Byers, MS, RBP, CBSP, President, ABSA,
6 September, 2011
ABSA comments on final draft of the CWA WS53 Biosafety Professional Competencies(PDF 44KB)
ABSA Comments on the July 21, 2010
Federal Register announcement regarding the biennial review and
republication of the Department of Health and Human Services (DHHS) list
of select agents and toxins. (PDF 140KB)
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA,
30 August, 2010
ABSA Comments on the proposed exemption of well-characterized transgenic animals from the NIH Guidelines.
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA,
10 August, 2010
ABSA Comments on the NIH Guidelines for
Research with Recombinant DNA
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA,
31 May, 2010
ABSA Comments on the Screening Framework Guidance for
Synthetic Double Stranded DNA Providers
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA,
21 January, 2010
ABSA Comments on the proposal to classify SARS as a Select Agent
a letter written by Robert Ellis, PhD, CBSP, President, ABSA,
11 September, 2009
Open Letter from the ABSA Legislative Committee(PDF 100KB); July 22, 2009
ABSA response to the NIH Guidelines for Research Involving Recombinant DNA Molecules(PDF 56KB); May 28, 2009
ABSA Comments on the Select Agent Program & Biosecurities Improvement Act(PDF 32KB); March 28, 2008
ABSA Position Paper on Accreditation of High Containment Laboratories(PDF 24KB); April 18, 2008
ABSA Comments on the Proposed Framework for the Oversight of Dual Use(PDF 92KB); Nov. 19, 2007
ABSA Comments Regarding the 5th Edition of the Biosafety in Microbiological and Biomedical Laboratories (BMBL). (PDF 108KB)
a letter written by Bill Homovec, MPH, CBSP, Chair and Co Team Leader, ABSA Technical and Regulatory Review Committee, May 2, 2007
ABSA Comments Regarding the Draft Pandemic Influenza Preparedness and Response Plan
a letter written by Elizabeth Gilman Duane, MS, RBP, CBSP, President, ABSA,
October 25, 2004
ABSA Comments Regarding Operational Issues of the CDC Select Agent Program
a letter written by Stefan Wagener, Ph.D., RBP, CBSP, President, ABSA,
6 April 2004
CDC Response to ABSA Comments Regarding the CDC Select Agent Program
ABSA Comments Regarding National Committee of Clinical Laboratory
Standard, NM29-3A, Protection of Laboratory Workers from
Occupationally-Acquired Infections
a letter written by Stefan Wagener, Ph.D., RBP, CBSP, President, ABSA, 5
April 2004
ABSA Comments on CDC Select Agent Rule
a letter written by Barbara Johnson, Ph.D., RBP, President, ABSA,
5 February 2003
Letter from the Biosecurity Task Force(PDF 496KB)
a letter written by Barbara Johnson, Ph.D., RBP, President-Elect, ABSA, and the ABSA Biosecurity Task Force, June 2002
ABSA Comments on Health Canada Revisions, American Biological Safety Association
a letter written by Debra Hunt, DrPh, RBP, CBSP,
Past-President, ABSA,
4 March 2002
CDC - "Draft Guideline for Hand Hygiene in Healthcare Settings"
a letter written by Maureen Best,
President, American Biological Safety Association,
7 December 2001
NIH Guidelines for Research Involving Recombinant DNA Molecules
a letter written by Debra Hunt, DrPH, RBP, CBSP (ABSA),
President, American Biological Safety Association,
10 September 2001
NCCLS - Protection of Laboratory Workers from Occupationally-Acquired Infections
a letter written by Debra Hunt, MT (ASCP), DrPH, CBSP (ABSA),
President, American Biological Safety Association,
29 August 2001
Response to: Hazardous Materials: Revision to Standards for Infectious Substances and Genetically Modified Microorganisms
a letter written by Debra Hunt, Dr.PH, RBP, CBSP (ABSA),
President, American Biological Safety Association,
18 April 2001
HIV Prevention Plan Comments
a letter written by Debra Hunt, Dr.PH, RBP, CBSP,
President, American Biological Safety Association,
5 February 2001
ABSA Response To: NIH Guidelines for Research Involving Recombinant DNA Molecules
a letter written by Debra Hunt, Dr.PH, RBP, CBSP (ABSA),
President, American Biological Safety Association,
February 2001
Arthropod Containment Guidelines (ACG)
a letter written by Debra L. Hunt, Dr.PH , RBP, CBSP (ABSA),
President, American Biological Safety Association,
February 2001
ABSA's Response to the "Needlestick Safety Prevention Act"
a letter written by John H. Keene, Dr.PH, CBSP (ABSA),
President, American Biological Safety Association,
17 October 2000
Institute of Medicine Response - Response to the OSHA TB Standard
a letter written by John H. Keene, Dr.PH, CBSP (ABSA) President,
American Biological Safety Association,
29 July 2000
ABSA comments on: 42 CFR Part 72 "Packaging and Handling of Infectious Substances and Select Agents" (CDC NPRM, 1999)
a letter written by John H. Keene, Dr.PH, CBSP (ABSA),
President, American Biological Safety Association,
21 December 1999

